Clinical trials: High Risk Medications
Heart Failure With Normal Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may…
- Conditions
- Heart Failure With Normal Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Heart Failure, Right Sided, Heart Failure With Mid Range Ejection Fraction
- Trial name
- PREFER-HF (NCT03480633)
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Learning Process in Nursing Graduation, Compliant Behavior
Effectiveness of High Fidelity Simulation for Safety in the Medication Process in Intensive Care
Nursing plays an important role in the medication process in intensive care units. The application of active methodologies guided by the simulation strategy can help in the formation of qualified professionals and in the safer…
- Trial name
- NCT03828526
- Testing
- High Fidelity Simulation, Traditional teaching strategy
- Where
- Brazil
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Brasilia
Ovarian Cancer, Peritoneal Cancer
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- GLORIOSA (NCT05445778)
- Testing
- Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab
- Where
- 264 sites in United States, Argentina and 20 more
- Volunteers
- 520 people
- Sponsor
- AbbVie
Anterior Cruciate Ligament
Efficacy of the SurgiStim3 Electrical Stimulation Device in Persons Undergoing Anterior Cruciate Ligament Repair
The purpose of this study is to determine whether a functional electrical stimulation device, the SurgiStim3, decreases pain, pain medications and/or edema in patients undergoing anterior cruciate ligament repair.
- Trial name
- NCT00717171
- Testing
- SurgiStim3
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VQ OrthoCare
Acute Mountain Sickness
Drug Combination on Exercise Performance at High Altitude
This study is being conducted to determine the effectiveness of using two FDA approved medications in concert to reduce the likelihood of sickness due to low oxygen levels and to reduce the decrement in physical performance at…
- Trial name
- NCT01902758
- Testing
- ambrisentan and theophylline
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Montana
Childhood Posterior Fossa Ependymoma
Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma
This phase I/II trial tests the safety, side effects best dose and how well giving fluorouracil and tretinoin along with standard of care radiation therapy works for the treatment of high risk posterior fossa ependymoma that has…
- Trial name
- NCT07848568
- Testing
- Biospecimen Collection, Echocardiography Test, Fluorouracil
- Volunteers
- 70 people
- Sponsor
- Children's Oncology Group
Metastatic Breast Cancer, Breast Cancer
Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer
In this phase I feasibility study, the investigators evaluate the combination of lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox) with local hyperthermia and cyclophosphamide (C), for the local treatment of the…
- Conditions
- Metastatic Breast Cancer, Breast Cancer, Breast Neoplasms, Stage IV Breast Cancer
- Trial name
- i-GO (NCT03749850)
- Testing
- LTLD, MR-HIFU induced hyperthermia, Cyclophosphamide
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- UMC Utrecht
Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation
Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial
This study sought to evaluate whether ezetimibe combination to high-intensity statin therapy will have more prominent beneficial effect compared to high-intensity statin monotherapy in patients who underwent coronary…
- Trial name
- NCT05782777
- Testing
- ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg), high-intensity statin monotherapy (atoravastatin 40mg)
- Where
- South Korea
- Volunteers
- 4,310 people
- Sponsor
- Yonsei University
Acquired Immune Deficiency Syndrome Virus, Hepatitis C
Brief Intervention for Rural Women at High Risk for HIV/HCV
The overall aim of this study is to reduce risk behaviors and increase health and behavioral health service utilization among disadvantaged, drug-using rural women at high risk for HIV and HCV.
- Conditions
- Acquired Immune Deficiency Syndrome Virus, Hepatitis C, Drug Abuse
- Trial name
- WISH (NCT01840722)
- Testing
- MI-based HIV Risk Reduction
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Michele Staton
Coronary Artery Disease
COmparison and Modification in Neointimal Pattern Assessed by Optical Coherence Tomography With High Versus Moderate Efficacy Statin Treatment After Drug Eluting Stent Implantation: COMPASS Trial
This study is a prospective randomized trial to evaluate and compare the quantitative and qualitative characteristics of neointimal formation between high and low efficacy statin treatment after drug eluting stent (DES)…
- Trial name
- NCT02155530
- Testing
- Atorvastatin 40mg, pravastatin 20 mg
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Yonsei University
Coronary Artery Disease
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
The primary objective is to determine the pharmacodynamic effect of ticagrelor dosing (180mg LD/ 90mg BID) at 2, 4 hours and 14 days in stable Coronary artery disease (CAD) patients who exhibit high-on prasugrel platelet…
- Trial name
- HEIGHTEN (NCT01869309)
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- LifeBridge Health
Clinical Deterioration, Hemodynamic Instability
Early Identification of Clinical Deterioration Using a Wearable Monitoring Device
This study aims to provide myriad of physiological parameters in patients admitted in an internal medicine department, and which are defined as being in an increased risk of clinical deterioration within the first 72-hours after…
- Trial name
- NCT04220359
- Testing
- non-invasive monitoring
- Where
- Israel
- Volunteers
- 410 people
- Sponsor
- Biobeat Technologies Ltd.
Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer.
- Conditions
- Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
- Trial name
- NCT06770582
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Where
- 147 sites in United States, Canada
- Volunteers
- 160 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Ovarian Cancer, Primary Peritoneal Cancer
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade…
- Conditions
- High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT05456685
- Testing
- Mirvetuximab soravtansine, Carboplatin
- Where
- 69 sites in United States, Belgium and 4 more
- Volunteers
- 125 people
- Sponsor
- AbbVie
Breast Neoplasms, Neoplasm Metastasis
Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients
To access the effectiveness of High-dose Cyclophosphamide Combined Chemotherapy combined with adoptive cellular therapy with dentritic and cytokine-induced killer cells in triple negative metastatic breast cancer patients
- Trial name
- DC-CIK (NCT01232062)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking University Cancer Hospital & Institute
Refractory Epilepsy in Children, Refractory Epilepsy
Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials
The goal of this clinical trial is to learn if cannabidiol ("CBD-oil") works to treat severe epilepsy in children. It will also learn about the safety of cannabidiol.
- Conditions
- Refractory Epilepsy in Children, Refractory Epilepsy, Epilepsy
- Trial name
- CBD-uN1que (NCT07668856)
- Testing
- Cannabidiol (CBD) oral solution
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- UMC Utrecht
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
This phase II trial studies how well olaparib with or without tremelimumab works in treating patients with ovarian, fallopian tube, or peritoneal cancer that has come back (recurrent).
- Conditions
- Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT04034927
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)